US-based stem cell medicine developer Clade Therapeutics received $87m in series A funding yesterday from investors including pharmaceutical firm Bristol Myers Squibb.
Life science-focused investment firm Syncona led the round, which also featured non-profit organisation Emerson Collective and LifeSci Venture Partners, the venture capital arm of healthcare advisory boutique LifeSci Partners.
Founded in 2020, Clade is working on cell transplantation-based therapies using technology which masks human pluripotent stem cells and their adult derivatives. It will channel the funding into further development of the platform.
Chad Cowan, Clade’s CEO, said: “We have reached an era in medicine where insights across genetic engineering, regenerative medicine and immunology have enabled a revolution of cell medicines.
“Clade was founded to overcome the clinical limitations of current cell therapies by addressing durability, patient compatibility, reproducibility and scalability to deliver on the transformative potential of this increasingly important therapeutic modality.”
